血管内皮细胞生长因子受体及其抑制剂的肿瘤治疗研究  

Study of VEGFR and its Inhibitors in the Treatment of Tumors

作　　者：王英娟[1] 赵玲娣[1] 司玉玲[1] 

机构地区：[1]天津市第四中心医院肿瘤血液科,天津300140

出　　处：《医学综述》2007年第20期1566-1568,共3页Medical Recapitulate

摘　　要：新生血管为肿瘤组织提供氧和营养物质,在肿瘤的生长与转移过程中起重要作用。肿瘤血管的形成是多种细胞因子综合作用的结果,在这些细胞因子中研究最多的是血管内皮细胞生长因子。血管内皮细胞生长因子与其受体结合后通过酪氨酸激酶途径引起细胞的增殖及新生血管形成。抑制血管内皮细胞生长因子介导的途径可使肿瘤缩小,目前抗血管内皮细胞生长因子治疗已成为靶向治疗的热点。The new vascular provides oxygen and nutrients for the tumors and plays an important role in its growth and metastasis. The formation of vascular in tumors is the result of interactions of many cytokines, among which vascular epithelial growth factor is the one studted most. Vascular epithelial growth factor binding with its receptor leads to cell proliferation and new vascular formation by tyrosine kinase pathway. The inhibition of this pathway may result in the shrinkage of tumor, At present, anti-VEGFR therapy is becoming the hot spot of its targeted therapy.

关 键 词：血管生成 血管内皮生长因子 血管内皮生长因子受体 

分 类 号：R73[医药卫生—肿瘤]